%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Bourgeois, Anke
%A Laurent, Christian
%A Mougnutou, R.
%A Nkoue, N.
%A Lactuock, B.
%A Ciaffi, L.
%A Liégeois, Florian
%A Andrieux Meyer, I.
%A Zekeng, L.
%A Calmy, A.
%A Mpoudi Ngolé, E.
%A Delaporte, Eric
%T Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon
%D 2005
%L PAR00000426
%G ENG
%J Antiviral Therapy
%@ 1359-6535
%M CC:0002319623-0016
%N 2
%P 335-341
%U https://www.documentation.ird.fr/hor/PAR00000426
%V 10
%W Horizon (IRD)
%X Objective: To assess the effectiveness of generic antiretroviral drugs in terms of survival and virological and immunological responses, as well as their tolerability and the emergence of viral resistance. Methods: A total of 109 HIV-1-infected patients were enrolled in a prospective cohort study in Yaounde, Cameroon. Available generic drugs were a fixed-dose combination (FDC) of zidovudine (ZDV) and lamivudine (3TC), an FDC of 3TC, stavudine (d4T) and nevirapine (NVP), and individual formulations of ZDV, 3TC and NVP. Results: At baseline, the median CD4 cell count was 150/mm(3) [interquartile range (IQR) 61-223] and median viral load was 5.4 log(10) copies/ml [IQR 4.8-5.6); 78% of patients received ZDV/3TC/NVP and 22% received 3TC/d4T/NVP. Median follow-up was 16 months (IQR 11-23). The survival probability was high (0.92 at 12 months); plasma viral load declined by a median of 3.3 log(10) copies/ml and 86.9% of the intention-to-treat population had viral load < 400 copies/ml at 12 months; CD4 count had increased by a median of 106 cells/mm(3) at 12 months; drug resistance rarely emerged (incidence rate 3.2 per 100 person-years); and the treatments were reasonably well-tolerated (incidence rate of severe adverse effects 7.8 per 100 person-years). Conclusion: Together with previous pharmacological and clinical studies, this prospective study suggests that these generic antiretroviral drugs can be used in developing countries.
%$ 052